Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl

Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce eleva...

Full description

Saved in:
Bibliographic Details
Published inClinical calcium Vol. 17; no. 1; p. 88
Main Authors Nakanishi, Shohei, Fukagawa, Masafumi
Format Journal Article
LanguageJapanese
Published Japan 01.01.2007
Subjects
Cinacalcet Hydrochloride
Clinical Trials as Topic
Humans
Hyperparathyroidism, Primary - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Kidney Failure, Chronic - drug therapy
Kidney Transplantation
Mutation
Naphthalenes - adverse effects
Naphthalenes - pharmacokinetics
Naphthalenes - pharmacology
Naphthalenes - therapeutic use
Parathyroid Hormone - secretion
Parathyroid Neoplasms - drug therapy
Receptors, Calcium-Sensing - agonists
Receptors, Calcium-Sensing - genetics
Online AccessGet more information

Cover

More Information
Summary:Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary hyperparathyroidism, but also secondary hyperparathyroidism in nondialyzed stage, renal transplant patients and parathyroid carcinoma.
ISSN:0917-5857